Alpha-synuclein inclusions reduced by PIKfyve inhibition in Parkinson disease cell models
These findings suggest that PIKfyve signalling pathways could represent a therapeutic target to reduce alpha-synuclein in PD.
Authors
- Derralynn Hughes (ORCID: https://orcid.org/0000-0003-4531-9173)
- Sara Lucas Del Pozo (ORCID: https://orcid.org/0000-0002-5431-8204)
- Kai‐Yin Chau (ORCID: https://orcid.org/0000-0002-5797-2922)
- Anthony H.V. Schapira (ORCID: https://orcid.org/0000-0002-3018-3966)
- Giuseppe Uras (ORCID: https://orcid.org/0000-0003-3494-8521)
- Sofia Koletsi (ORCID: https://orcid.org/0000-0002-6661-7797)
- Veronica Lentini (ORCID: https://orcid.org/0009-0000-6060-0321)
- Federico Fierli (ORCID: https://orcid.org/0000-0002-8259-2067)
- Carlos Lazaro-Hernandez
Institutions
- University of Sassari (IT)
- Royal Free London NHS Foundation Trust (GB)
- King's College London (GB)
- Vall d'Hebron Institut de Recerca (ES)
- MRC Prion Unit (GB)
- University College London (GB)
Publication Details
- Journal
- Neurobiology of Disease
- Published
- 2025-08-12
- DOI
- https://doi.org/10.1016/j.nbd.2025.107053
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Aligning Science Across Parkinson’s